Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist.

Trial Profile

Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2011

At a glance

  • Drugs MK 0777 (Primary)
  • Indications Cognition disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2011 Actual end date (January 2008) added as reported by ClinicalTrials.gov.
    • 15 Oct 2011 Primary endpoint identified as Continuous Performance Test as reported by ClinicalTrials.gov.
    • 30 Mar 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top